drugset
drugset / Trial / NCT01054014

A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers

NCT01054014 ↗

Phase 1 Completed 120 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and it is removed from the body over time) of single and multiple doses of JNJ-40346527 in healthy volunteers. This study will also investigate the pharmacokinetics of JNJ-40346527 with and without food.

Timeline

Start
2010-01
Primary completion
—
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-40346527 Unknown 10 mg Oral
Subject JNJ-40346527 Unknown 50 mg Oral
Subject JNJ-40346527 Unknown 150 mg Oral
Subject JNJ-40346527 Unknown 300 mg Oral
Subject JNJ-40346527 Unknown 500 mg Oral
Subject JNJ-40346527 Unknown 600 mg Oral
Subject JNJ-40346527 Unknown 750 mg Oral
Subject JNJ-40346527 Unknown 1000 mg Oral

Indications

No indication recorded.